Maiwald Magazine

Press Coverage

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

9 Jul 2025 - Press Coverage

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.

24 Jun 2025 - Press Release

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Maiwald in the press

Publications

11 Jun 2025 - Publication

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

In their recent feature with Managing IP, senior representatives from Maiwald – Dr. Anja Fux, Dr. Derk Vos, Heike Roeder-Hitschke, Dr. Nils Braun and Martina Boidol...

30 Apr 2025 - Publication

Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

This article covers the most recent developments regarding the European Research Exemption, which permits the use of patented inventions for research purposes, as well as the ...

30 Apr 2025 - Publication

The ‘long-arm’ of the Unified Patent Court – New developments in European cross-border patent litigation, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

The jurisdictional reach of the Unified Patent Court (UPC) was a widely and controversially discussed topic from the outset. Some practitioners took the view that the UPC also...

All publications

Events

Sun.

28 Sep 2025 |Upcoming|External Events

Maiwald at TMAP 2025 in Berlin, September 28-30, 2025

We are pleased to participate in the INTA Trademark Administrators & Practitioners (TMAP) Meeting 2025 in Berlin. This prestigious event brings together trademark administrators, patent paralegals, young professionals and attorneys working in the field of trademark law.The diverse conference program will cover current developments in trademark law and practical top...

Mon.

13 Oct 2025 |Upcoming

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

We are pleased to announce that Maiwald Intellectual Property will participate as a Platinum Partner at the upcoming Life Sciences Strategy Summit on IP & Exclusivity, taking place in the Infinity Hotel & Conference Resort Munich from 13–15 October 2025.

Wed.

21 May 2025 |Past Event|External Events

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam

We are pleased that Dr. Eva Ehlich was an expert at the 18th C5 Communications Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam. Eva gave a presentation on “Plausibility and Post-Publication Evidence in Inventive Step ...

Tue.

20 May 2025 |Past Event|Vortag Live

Joint symposium with Oblon in Tokyo on May 20, 2025

The Oblon and Maiwald firms were pleased to host a complimentary joint international symposium on:U.S. and European Patent Practice: Important Aspects for Practitioners At the 2025 joint symposium, selected current aspects of protecting innovations in the U.S. and Europe were examined, considering bo...

All events

News and Releases

Maiwald Blog

Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Staff News

Maiwald appoints Alexander Feil, Dr. Johannes Scholz and Dr. Fabian Wiescher as Counsel

Dr. Patrick Heeger and Dr. Andre Mähringer sworn in as German patent attorneys

Maiwald congratulates Dr. Anna Closs on passing the exam

Publications

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

The ‘long-arm’ of the Unified Patent Court – New developments in European cross-border patent litigation, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

Awards

2025 IP Stars Patent Rankings in the categories “Patent Prosecution” and “Patent Disputes” revealed

Dr. Marco Stief honoured as Thought Leader Germany, Lexology Index 2025

Leaders League Ranking Germany 2025

Events

Maiwald at TMAP 2025 in Berlin, September 28-30, 2025

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam

Joint symposium with Oblon in Tokyo on May 20, 2025